LBLinda Bertoldo

Linda Bertoldo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linda Bertoldo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Breast Cancer and Ovarian Tissue Cryopreservation: SWOT Analysis

    by Diego Raimondo, Marisol Doglioli, Cristian Forastiere, Rossella Vicenti, Marco Schirripa, Enrico Pazzaglia, Michele Miscia, Daniele Neola, Linda Bertoldo, Maria Massucci, et al.

    Background/Objectives: Breast cancer is the most common malignancy in young women, many of whom face fertility impairment due to gonadotoxic treatments and prolonged endocrine therapy. Ovarian tissue cryopreservation (OTC) has emerged as an alternative fertility preservation (FP) strategy, particularly when controlled ovarian stimulation is not feasible. This study aimed to evaluate the role of OTC in breast cancer patients, with the aim of clarifying its current clinical role and future perspectives within fertility preservation counselling for this population. Methods: A structured SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis was conducted based on the current literature, addressing clinical efficacy, safety, and applicability of OTC in breast cancer patients. Results: Key strengths of OTC include the absence of delay in cancer treatment and the potential to restore both endocrine and reproductive function. However, limitations include the need for surgery, the theoretical risk of reintroducing malignant cells, and variable, less predictable reproductive outcomes compared with gamete-based strategies. Opportunities lie in advances in cryopreservation, transplantation techniques, and integration with in vitro maturation. Major threats include limited data in breast cancer-specific populations, challenges in BRCA mutation carriers, and low utilization rates affecting cost-effectiveness and healthcare sustainability. Conclusions: OTC represents a valuable complementary FP option for selected breast cancer patients, particularly in urgent settings. Despite promising outcomes, its use should remain individualized within multidisciplinary counseling, considering patient-specific oncological and reproductive factors, while further research is needed to clarify long-term safety and efficacy.